New combo therapy aims to tame rare blood cancer
NCT ID NCT07444710
First seen Mar 23, 2026 · Last updated May 01, 2026 · Updated 6 times
Summary
This early-stage study tests the safety and best dose of the drug glofitamab when given with standard chemotherapy for people with untreated mantle cell lymphoma, a rare blood cancer. About 16 adults aged 18 to 75 with advanced disease will participate. The goal is to see if adding glofitamab to chemo is safe and tolerable.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANN ARBOR STAGE II MANTLE CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.